13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • Research home > Beat Cancer Project search > Investigating Desmoglein-2 as a Superior Biomarker and Therapeutic Target for Multiple Myeloma

    Investigating Desmoglein-2 as a Superior Biomarker and Therapeutic Target for Multiple Myeloma

    Dr Craig Wallington-Beddoe

    Multiple myeloma (MM) is an incurable aggressive cancer of the bone marrow. In Australia, 1,876 new cases were diagnosed in 2018 with an estimated 5 year survival rate of 50% and treatment costs exceeding $700,000/patient. We have identified desmoglein-2 (DSG2), a cell surface protein, to be elevated in 35% of MM patients who are 3 times more likely to die within 6 years of diagnosis. This study examines a new prognostic tool to rapidly identify these patients and new DSG2-targeting therapies.



  • Apply for funding

    Apply for funding

    Find out more about applications for funding.

  • Cancer statistics

    Cancer statistics

    Access the latest cancer statistics for South Australia

  • Clinical trials

    Clinical trials

    Access the list of current clinical trials taking place in South Australia.